GlaxoSmithKline (GSK) – To cut 900 research and sales jobs

GlaxoSmithKline (GSK.L) is to shed hundreds of U.S. commercial and research jobs, restructuring operations in its biggest market where drug sales are flagging.

A total of 900 posts will be eliminated at GSK’s Research Triangle Park site in North Carolina as drug research is consolidated in Philadelphia and in Stevenage, near London, according to a filing with the North Carolina Department of Commerce. (here)

GSK, however, said some staff would be offered the chance to relocate to other sites.

“This is a significant program and will result in the loss of several hundred employees in the U.S. commercial business and a similar number in R&D activities based in the U.S.,” a company spokesman said in an emailed statement.

Chosen excerpts by Job Market Monitor. Read the whole story at GSK cuts U.S. research and sales jobs as market gets tougher | Reuters.